35-7-1802. Definitions. (a) As used in this article: (i) 'Eligible patient' means a person who has: (A) A terminal illness; (B) Considered all other treatment options currently approved by the United States food and drug administration; (C) Received a recommendation from a physician for an investigational drug, biological product or device; (D) Given written, informed consent for the use of the investigational drug, biological product or device or, if the patient is a minor or lacks the mental capacity to provide informed consent, a parent or legal guardian has given written informed consent on the patient's behalf; and (E) Documentation from a physician that the person meets the requirements of this paragraph. (ii) 'Investigational drug, biological product or device' means a drug, biological product or device that has successfully completed phase one of a clinical trial but has not yet been approved for general use by the United States Food and Drug Administration and remains under investigation in a clinical trial; (iii) 'Terminal illness' means a disease that, without life-sustaining procedures, will soon result in death or a state of permanent unconsciousness from which nder investigation in a clinical trial; (iii) 'Terminal illness' means a disease that, without life-sustaining procedures, will soon result in death or a state of permanent unconsciousness from which recovery is unlikely.
Wyoming Legal Code